logo-loader
RNS
Physiomics PLC

Change of Adviser

/**/ h1{margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;text-align:center;font-size:16.0pt;font-family:"Trebuchet MS","sans-serif";}h3{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Trebuchet MS","sans-serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .al{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.al{}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; line-height: 110%; margin-bottom: 0cm}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: 110%}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; line-height: 110%; margin-bottom: 0cm; text-align: center}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; line-height: 110%; margin-bottom: 0cm; text-align: center; text-autospace: none}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";line-height: 110%; margin-bottom: 0cm; text-align: center; text-autospace: none}p.bf{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; line-height:110%}span.at{font-size:11.0pt;line-height:110%;font-family: "Trebuchet MS","sans-serif"}span.as{font-size:11.0pt;line-height:110%;font-family:"Trebuchet MS","sans-serif"} p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:110%;text-autospace:none}p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:110%}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; line-height: 110%; margin-bottom: 0cm; text-align: justify}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; line-height: 110%; margin-bottom: 0cm; text-align: justify; text-autospace: none}span.an{font-size:10.0pt; line-height:110%} /**/
RNS Number : 6677A
Physiomics PLC
31 May 2019
 

31 May 2019

 

Physiomics plc

("Physiomics") or (the "Company")

 

Change of Adviser

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has appointed Strand Hanson Limited as its Nominated and Financial Adviser, with immediate effect.

 

Hybridan LLP will continue to act as the Company's sole broker.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 20 3764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPURRNRKVAVOAR

Quick facts: Physiomics PLC

Price: 2.6

Market: AIM
Market Cap: £1.87 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE